199 related articles for article (PubMed ID: 18175285)
1. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review.
Mina A; Favaloro EJ; Koutts J
Semin Thromb Hemost; 2007 Nov; 33(8):798-809. PubMed ID: 18175285
[TBL] [Abstract][Full Text] [Related]
2. [Role of the hemostatic system in pathogenesis of atherosclerosis as the main etiology of coronary ischemia] [corrected].
Lisowski P; Małyszko J; Lisowska A; Czech B; Myśliwiec M; Jackowski R; Hirnle T
Pol Merkur Lekarski; 2004 May; 16(95):465-7. PubMed ID: 15518428
[TBL] [Abstract][Full Text] [Related]
3. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent?
Yudkin JS
Diabetes Care; 1999 Apr; 22 Suppl 3():C25-30. PubMed ID: 10189559
[TBL] [Abstract][Full Text] [Related]
4. Endothelial dysfunction in the pathogenesis of atherosclerosis.
Poredos P
Int Angiol; 2002 Jun; 21(2):109-16. PubMed ID: 12110769
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
Favaloro EJ
Semin Thromb Hemost; 2008 Feb; 34(1):113-27. PubMed ID: 18393148
[TBL] [Abstract][Full Text] [Related]
6. Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men.
Wannamethee SG; Sattar N; Rumley A; Whincup PH; Lennon L; Lowe GD
Diabetes Care; 2008 May; 31(5):995-1000. PubMed ID: 18235054
[TBL] [Abstract][Full Text] [Related]
7. Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease.
Kamiński TW; Pawlak K; Karbowska M; Myśliwiec M; Pawlak D
BMC Nephrol; 2017 Jan; 18(1):35. PubMed ID: 28122514
[TBL] [Abstract][Full Text] [Related]
8. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers.
Soares AL; Sousa Mde O; Dusse LM; Fernandes AP; Lasmar MC; Novelli BA; Lages Gde F; Carvalho Md
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):395-9. PubMed ID: 17581312
[TBL] [Abstract][Full Text] [Related]
10. [Role of the hemostasis in unstable angina pectoris].
Lisowski P; Małyszko J; Lisowska A; Czech B; Myśliwiec M; Jackowski R; Hirnle T
Pol Merkur Lekarski; 2004 May; 16(95):468-71. PubMed ID: 15518429
[TBL] [Abstract][Full Text] [Related]
11. Circulating markers of endothelial function in cardiovascular disease.
Constans J; Conri C
Clin Chim Acta; 2006 Jun; 368(1-2):33-47. PubMed ID: 16530177
[TBL] [Abstract][Full Text] [Related]
12. Novel biomedical risk markers for cardiovascular disease.
Magliano DJ; Liew D; Ashton EL; Sundararajan V; McNeil JJ
J Cardiovasc Risk; 2003 Feb; 10(1):41-55. PubMed ID: 12569236
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome.
Moran LJ; Hutchison SK; Meyer C; Zoungas S; Teede HJ
Clin Sci (Lond); 2009 May; 116(10):761-70. PubMed ID: 18851710
[TBL] [Abstract][Full Text] [Related]
14. [Acquired von Willebrand syndrome].
Franchini M
Recenti Prog Med; 2006; 97(7-8):417-21; quiz 440. PubMed ID: 16913181
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome.
Kuşçu NK; Var A
Acta Obstet Gynecol Scand; 2009; 88(5):612-7. PubMed ID: 19308750
[TBL] [Abstract][Full Text] [Related]
16. Effects of insulin resistance on endothelial progenitor cells and vascular repair.
Cubbon RM; Kahn MB; Wheatcroft SB
Clin Sci (Lond); 2009 Aug; 117(5):173-90. PubMed ID: 19630751
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
18. Platelet dysfunction in central obesity.
Anfossi G; Russo I; Trovati M
Nutr Metab Cardiovasc Dis; 2009 Jul; 19(6):440-9. PubMed ID: 19346117
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of hyperglycaemia on plasma concentration of soluble P-selectin and von Willebrand factor in healthy volunteers -a prospective randomised double blind controlled study.
Kotzailias N; Graninger M; Knechtelsdorfer M; Jilma B
Thromb Res; 2009; 123(3):452-9. PubMed ID: 18707755
[TBL] [Abstract][Full Text] [Related]
20. Endothelial haemostatic markers in members of families with familial combined hyperlipidemia.
Karásek D; Vaverková H; Halenka M; Slavík L; Novotný D
Thromb Res; 2009; 123(3):466-75. PubMed ID: 18417194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
